Workflow
调研速递|海南海药接受北京诚旸投资等3家机构调研 创新药研发进展成焦点

Group 1 - The company conducted an investor relations activity focusing on the progress of innovative drug research and development, overseas rights cooperation, resolution of industry competition, and layout in the health sector [2] - The company is currently conducting Phase IIa clinical trials for the innovative drug Painegabine, with 100% enrollment of the target 36 participants, and expects to unblind and read results by the end of 2025 [2] - The company has completed the Phase II clinical trial for Fluofenone and is preparing for Phase III clinical trials, with data expected to be read out by the end of this year [2] Group 2 - The company is actively seeking suitable partners for overseas rights cooperation for Painegabine [2] - The company is addressing industry competition commitments with a focus on resolution [2] - The company has partnered with AFT Pharmaceuticals from New Zealand to become the exclusive sales agent for five products and signed a strategic cooperation agreement with Malaysia's Aikang International Group to leverage the Hainan Free Trade Port policy [2] Group 3 - The company plans to focus on the neuropsychiatric field, introducing a long-acting injection of Paliperidone for schizophrenia treatment, and aims to develop a product cluster [2] - The company is enhancing its product pipeline in traditional Chinese medicine, focusing on gastrointestinal health products, and aims to expand overseas registration and sales [2] - The company is deepening collaborations with universities and research institutions to explore high-end formulations and international partnerships [2]